早期强化他汀治疗对急性冠脉综合征患者血清中MMP-8及TIMP-1水平的影响

Effect of intensive atorvastatin therapy on MMP-8 and TIMP-1 in patients with acute coronary syndrome

目的:探讨早期强化他汀治疗对急性冠脉综合征(ACS)患者血清中基质金属蛋白酶8(MMP-8)和组织抑制因子1(TIMP-1)水平的影响。方法:ACS患者148例,随机分为常规他汀组(阿托伐他汀20 mg/d)和强化他汀组(阿托伐他汀40mg/d),治疗1月后观察两组治疗前后MMP-8和TIMP-1水平的变化。结果:两组治疗后血清中MMP-8均下降,强化组下降明显(P<0.05),而TIMP-1均有升高,强化组上升显著(P<0.05)。结论:早期大剂量应用阿托伐他汀治疗可降低ACS患者血清MMP-8水平和升高TIMP-1水平,抑制炎性反应,促进斑块的稳定。

Objective： To explore the effect of intensive atorvastatin therapy on serum levels of matrix metalloproteinase- 8 （MMP- 8） and tissue inhibitor of metalloproteinase- 1 （TIMP- 1 ） in patients with acute coronary syndrome（ACS）. Methods： A total of 148 patients with ACS were randomly divided into intensive atorvastatin therapy group （74 cases） and moderate atorvastatin therapy group （74 cases）. After treatment for 1 month, the serum levels of MMP-8 and TIMP-1 were measured by enzyme-linked immunosorbent assay （ELISA） and analyzed. Results： The serum levels of MMP-8 were significantly decreased in two groups compared with pro-treatment, serum levels of TIMP-1 in the two groups were significantly higher than that of pro-treatment, but it was significantly higher in intensive：atorvastatin group than that of atorvastatin group（P〈0.05）. Conclusion： The effect of intensive atorvastatin therapy on serum levels of MMP-8 and TIMP-1 in patients with ACS contributes to suppression of inflammation response, matrix degradation, and the stability of atherosclerosis plaque.